Skip to main content
Top
Published in: Familial Cancer 2/2012

Open Access 01-06-2012 | Original Article

Urologists’ and GPs’ knowledge of hereditary prostate cancer is suboptimal for prostate cancer counseling: a nation-wide survey in The Netherlands

Authors: Ruben Cremers, Christi van Asperen, Paul Kil, Hans Vasen, Tjerk Wiersma, Inge van Oort, Lambertus Kiemeney

Published in: Familial Cancer | Issue 2/2012

Login to get access

Abstract

A family history of prostate cancer (PCa) is an established risk factor for PCa. In case of a positive family history, the balance between positive and adverse effects of prostate-specific antigen (PSA) testing might be different from the general population, for which the European Randomized Study of Screening for Prostate Cancer (ERSPC) showed a beneficial effect on mortality. This, however, went at the cost of considerable overtreatment. This study assessed Dutch physicians’ knowledge of heredity and PCa and their ‘post-ERSPC’ attitude towards PCa testing, including consideration of family history. In January 2010, all Dutch urologists and clinical geneticists (CGs) and 300 general practitioners (GPs) were invited by email to complete an anonymous online survey, which contained questions about hereditary PCa and their attitudes towards PCa case-finding and screening. 109 urologists (31%), 69 GPs (23%) and 46 CGs (31%) completed the survey. CGs had the most accurate knowledge of hereditary PCa. All but 1 CG mentioned at least one inherited trait with PCa, compared to only 25% of urologists and 9% of GPs. CGs hardly ever counseled men about PCa testing. Most urologists and GPs discuss possible risks and benefits before testing for PCa with PSA. Remarkably, 35–40% of them do not take family history into consideration. Knowledge of urologists and GPs about heredity and PCa is suboptimal. Hence, PCa counseling might not be optimal for men with a positive family history. Multidisciplinary guidelines on this topic should be developed to optimize personalized counseling.
Literature
1.
go back to reference Brandt A, Bermejo JL, Sundquist J, Hemminki K (2010) Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members. Eur Urol 58(2):275–280PubMedCrossRef Brandt A, Bermejo JL, Sundquist J, Hemminki K (2010) Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members. Eur Urol 58(2):275–280PubMedCrossRef
2.
go back to reference Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC (1993) Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150(3):797–802PubMed Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC (1993) Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150(3):797–802PubMed
3.
go back to reference Langeberg WJ, Isaacs WB, Stanford JL (2007) Genetic etiology of hereditary prostate cancer. Front Biosci 12:4101–4110PubMedCrossRef Langeberg WJ, Isaacs WB, Stanford JL (2007) Genetic etiology of hereditary prostate cancer. Front Biosci 12:4101–4110PubMedCrossRef
4.
go back to reference Fletcher O, Houlston RS (2010) Architecture of inherited susceptibility to common cancer. Nat Rev Cancer 10(5):353–361PubMedCrossRef Fletcher O, Houlston RS (2010) Architecture of inherited susceptibility to common cancer. Nat Rev Cancer 10(5):353–361PubMedCrossRef
5.
go back to reference Varghese JS, Easton DF (2010) Genome-wide association studies in common cancers–what have we learnt? Curr Opin Genet Dev 20(3):201–209PubMedCrossRef Varghese JS, Easton DF (2010) Genome-wide association studies in common cancers–what have we learnt? Curr Opin Genet Dev 20(3):201–209PubMedCrossRef
6.
go back to reference Gudmundsson J, Besenbacher S, Sulem P, Gudbjartsson DF, Olafsson I, Arinbjarnarson S, Agnarsson BA, Benediktsdottir KR, Isaksson HJ, Kostic JP, Gudjonsson SA, Stacey SN, Gylfason A, Sigurdsson A, Holm H, Bjornsdottir US, Eyjolfsson GI, Navarrete S, Fuertes F, Garcia-Prats MD, Polo E, Checherita IA, Jinga M, Badea P, Aben KK, Schalken JA, van OI, Sweep FC, Helfand BT, Davis M, Donovan JL, Hamdy FC, Kristjansson K, Gulcher JR, Masson G, Kong A, Catalona WJ, Mayordomo JI, Geirsson G, Einarsson GV, Barkardottir RB, Jonsson E, Jinga V, Mates D, Kiemeney LA, Neal DE, Thorsteinsdottir U, Rafnar T, Stefansson K (2010) Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med 2(62):62ra92PubMedCrossRef Gudmundsson J, Besenbacher S, Sulem P, Gudbjartsson DF, Olafsson I, Arinbjarnarson S, Agnarsson BA, Benediktsdottir KR, Isaksson HJ, Kostic JP, Gudjonsson SA, Stacey SN, Gylfason A, Sigurdsson A, Holm H, Bjornsdottir US, Eyjolfsson GI, Navarrete S, Fuertes F, Garcia-Prats MD, Polo E, Checherita IA, Jinga M, Badea P, Aben KK, Schalken JA, van OI, Sweep FC, Helfand BT, Davis M, Donovan JL, Hamdy FC, Kristjansson K, Gulcher JR, Masson G, Kong A, Catalona WJ, Mayordomo JI, Geirsson G, Einarsson GV, Barkardottir RB, Jonsson E, Jinga V, Mates D, Kiemeney LA, Neal DE, Thorsteinsdottir U, Rafnar T, Stefansson K (2010) Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med 2(62):62ra92PubMedCrossRef
7.
go back to reference Kote-Jarai Z, Amin Al Olama A, Leongamornlert D, Tymrakiewicz M, Saunders E, Guy M, Giles GG, Severi G, Southey M, Hopper JL, Sit KC, Harris JM, Batra J, Spurdle AB, Clements JA, Hamdy F, Neal D, Donovan J, Muir K, Pharoah PD, Chanock SJ, Brown N, Benlloch S, Castro E, Mahmud N, O’Brien L, Hall A, Sawyer E, Wilkinson R, Easton DF, Eeles RA (2011) Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum Genet 129(6):687–694. doi:10.1007/s00439-011-0981-1 PubMedCrossRef Kote-Jarai Z, Amin Al Olama A, Leongamornlert D, Tymrakiewicz M, Saunders E, Guy M, Giles GG, Severi G, Southey M, Hopper JL, Sit KC, Harris JM, Batra J, Spurdle AB, Clements JA, Hamdy F, Neal D, Donovan J, Muir K, Pharoah PD, Chanock SJ, Brown N, Benlloch S, Castro E, Mahmud N, O’Brien L, Hall A, Sawyer E, Wilkinson R, Easton DF, Eeles RA (2011) Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum Genet 129(6):687–694. doi:10.​1007/​s00439-011-0981-1 PubMedCrossRef
8.
go back to reference Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317(15):909–916PubMedCrossRef Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317(15):909–916PubMedCrossRef
9.
go back to reference Roobol MJ, Kerkhof M, Schroder FH, Cuzick J, Sasieni P, Hakama M, Stenman UH, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis L, Recker F, Berenguer A, Ruutu M, Kujala P, Bangma CH, Aus G, Tammela TL, Villers A, Rebillard X, Moss SM, de Koning HJ, Hugosson J, Auvinen A (2009) Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 56(4):584–591PubMedCrossRef Roobol MJ, Kerkhof M, Schroder FH, Cuzick J, Sasieni P, Hakama M, Stenman UH, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis L, Recker F, Berenguer A, Ruutu M, Kujala P, Bangma CH, Aus G, Tammela TL, Villers A, Rebillard X, Moss SM, de Koning HJ, Hugosson J, Auvinen A (2009) Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 56(4):584–591PubMedCrossRef
10.
go back to reference Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der KT, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320–1328PubMedCrossRef Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der KT, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320–1328PubMedCrossRef
11.
go back to reference Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310–1319PubMedCrossRef Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310–1319PubMedCrossRef
12.
go back to reference Schroder FH, Roobol MJ (2010) ERSPC and PLCO prostate cancer screening studies: what are the differences? Eur Urol 58(1):46–52PubMedCrossRef Schroder FH, Roobol MJ (2010) ERSPC and PLCO prostate cancer screening studies: what are the differences? Eur Urol 58(1):46–52PubMedCrossRef
13.
go back to reference Kiemeney LA, Broeders MJ, Pelger M, Kil PJ, Schroder FH, Witjes JA, Vasen HF (2008) Screening for prostate cancer in Dutch hereditary prostate cancer families. Int J Cancer 122(4):871–876PubMedCrossRef Kiemeney LA, Broeders MJ, Pelger M, Kil PJ, Schroder FH, Witjes JA, Vasen HF (2008) Screening for prostate cancer in Dutch hereditary prostate cancer families. Int J Cancer 122(4):871–876PubMedCrossRef
14.
go back to reference Valeri A, Cormier L, Moineau MP, Cancel-Tassin G, Azzouzi R, Doucet L, Baschet F, Cussenot I, L’Her J, Berthon P, Mangin P, Cussenot O, Morin JF, Fournier G (2002) Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives. J Urol 168(2):483–487. doi:S0022-5347(05)64663-0 PubMedCrossRef Valeri A, Cormier L, Moineau MP, Cancel-Tassin G, Azzouzi R, Doucet L, Baschet F, Cussenot I, L’Her J, Berthon P, Mangin P, Cussenot O, Morin JF, Fournier G (2002) Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives. J Urol 168(2):483–487. doi:S0022-5347(05)64663-0 PubMedCrossRef
15.
go back to reference Bratt O, Garmo H, Adolfsson J, Bill-Axelson A, Holmberg L, Lambe M, Stattin P (2010) Effects of prostate-specific antigen testing on familial prostate cancer risk estimates. J Natl Cancer Inst 102(17):1336–1343. doi:10.1093/jnci/djq265 PubMedCrossRef Bratt O, Garmo H, Adolfsson J, Bill-Axelson A, Holmberg L, Lambe M, Stattin P (2010) Effects of prostate-specific antigen testing on familial prostate cancer risk estimates. J Natl Cancer Inst 102(17):1336–1343. doi:10.​1093/​jnci/​djq265 PubMedCrossRef
18.
go back to reference Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22(4):735–742PubMedCrossRef Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22(4):735–742PubMedCrossRef
19.
go back to reference Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, Cummings S, Olopade O, Stoppa-Lyonnet D, Couch F, Wagner T, Warner E, Foulkes WD, Saal H, Weitzel J, Tulman A, Poll A, Nam R, Sun P, Danquah J, Domchek S, Tung N, Ainsworth P, Horsman D, Kim-Sing C, Maugard C, Eisen A, Daly M, McKinnon W, Wood M, Isaacs C, Gilchrist D, Karlan B, Nedelcu R, Meschino W, Garber J, Pasini B, Manoukian S, Bellati C (2008) Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 99(2):371–374PubMedCrossRef Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, Cummings S, Olopade O, Stoppa-Lyonnet D, Couch F, Wagner T, Warner E, Foulkes WD, Saal H, Weitzel J, Tulman A, Poll A, Nam R, Sun P, Danquah J, Domchek S, Tung N, Ainsworth P, Horsman D, Kim-Sing C, Maugard C, Eisen A, Daly M, McKinnon W, Wood M, Isaacs C, Gilchrist D, Karlan B, Nedelcu R, Meschino W, Garber J, Pasini B, Manoukian S, Bellati C (2008) Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 99(2):371–374PubMedCrossRef
20.
go back to reference Grindedal EM, Moller P, Eeles R, Stormorken AT, Bowitz-Lothe IM, Landro SM, Clark N, Kvale R, Shanley S, Maehle L (2009) Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer EpidemiolBiomarkers Prev 18(9):2460–2467CrossRef Grindedal EM, Moller P, Eeles R, Stormorken AT, Bowitz-Lothe IM, Landro SM, Clark N, Kvale R, Shanley S, Maehle L (2009) Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer EpidemiolBiomarkers Prev 18(9):2460–2467CrossRef
21.
go back to reference Gronberg H, Damber L, Tavelin B, Damber JE (1998) No difference in survival between sporadic, familial and hereditary prostate cancer. Br J Urol 82(4):564–567PubMedCrossRef Gronberg H, Damber L, Tavelin B, Damber JE (1998) No difference in survival between sporadic, familial and hereditary prostate cancer. Br J Urol 82(4):564–567PubMedCrossRef
22.
go back to reference Kupelian PA, Reddy CA, Reuther AM, Mahadevan A, Ciezki JP, Klein EA (2006) Aggressiveness of familial prostate cancer. J Clin Oncol 24(21):3445–3450PubMedCrossRef Kupelian PA, Reddy CA, Reuther AM, Mahadevan A, Ciezki JP, Klein EA (2006) Aggressiveness of familial prostate cancer. J Clin Oncol 24(21):3445–3450PubMedCrossRef
23.
go back to reference Kranse R, Roobol M, Schroder FH (2008) A graphical device to represent the outcomes of a logistic regression analysis. Prostate 68(15):1674–1680PubMedCrossRef Kranse R, Roobol M, Schroder FH (2008) A graphical device to represent the outcomes of a logistic regression analysis. Prostate 68(15):1674–1680PubMedCrossRef
Metadata
Title
Urologists’ and GPs’ knowledge of hereditary prostate cancer is suboptimal for prostate cancer counseling: a nation-wide survey in The Netherlands
Authors
Ruben Cremers
Christi van Asperen
Paul Kil
Hans Vasen
Tjerk Wiersma
Inge van Oort
Lambertus Kiemeney
Publication date
01-06-2012
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2012
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-011-9500-8

Other articles of this Issue 2/2012

Familial Cancer 2/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine